No quarterly revenue total was found in IMMUNOVANT, INC.'s SEC filings.
Immunovant, Inc. (IMVT) files with the SEC under industry code 2836, Biological Products, (No Diagnostic Substances).
Revenue
—
Net income
$-153.22M
-27.0% vs year-ago quarter
Operating cash flow
$-124.41M
-6.0% vs year-ago quarter
Free cash flow
$-95.07M
+14.2% vs year-ago quarter
EPS
$-0.75
-5.6% vs year-ago quarter
Dividend per share
None
Shares outstanding
206.55M
+18.5% vs year-ago quarter
Net cash
$902.04M
Q4 FY2026
Operating margin
—
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- IMVT (Nasdaq)
- Fiscal year ends
- March 31
- Incorporated in
- DE
- Headquarters
- Durham, NC
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1764013
- Former names
- Health Sciences Acquisitions Corp (until Dec 20, 2019)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q1 FY2027 Jun 30, 2026 |
Q4 FY2026 Mar 31, 2026 |
Q3 FY2026 Dec 31, 2025 |
Q2 FY2026 Sep 30, 2025 |
Q1 FY2026 Jun 30, 2025 |
|---|---|---|---|---|---|
| Net income | -$153.2M | -$147.9M | -$110.6M | -$126.5M | -$120.6M |
| Diluted EPS | -$0.75 | -$0.73 | -$0.61 | -$0.73 | -$0.71 |
| Operating cash flow | -$124.4M | -$95.1M | -$92.3M | -$102.5M | -$117.4M |
| Free cash flow | — | -$95.1M | -$92.3M | -$102.5M | -$117.4M |
| Total assets | $852.5M | $957.0M | $1.1B | $583.0M | $661.4M |
| Total liabilities | $117.1M | $104.4M | $66.3M | $63.3M | $52.9M |
| Stockholders' equity | $735.4M | $852.6M | $986.1M | $519.7M | $608.5M |
| Cash and investments | $797.8M | $902.1M | $994.5M | $521.9M | $598.9M |
| Total debt | — | $72,000 | — | — | — |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Shareholder vote results
|
Sep 3, 2026 | Sep 2, 2026 |
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| ARS | Annual report to shareholders | Jul 22, 2026 | Mar 31, 2026 |
| 10-K | Annual report | May 20, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 20, 2026 | May 20, 2026 |
All 648 Immunovant, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.